Form 4: Tourmaline Bio Director Acquires Stock Options

Director Aaron Kantoff acquired stock options in Tourmaline Bio, Inc. on June 5, 2024.

Summary

• On June 5, 2024, Aaron Kantoff, a director of Tourmaline Bio, Inc., acquired stock options.
• The options grant the right to buy 10,000 shares of common stock at an exercise price of $13.91.
• The options vest on the earlier of the anniversary of the transaction date or the date of the Issuer's 2025 Annual Meeting of Stockholders, contingent upon continued service.
• Following the transaction, Kantoff directly owns 10,000 derivative securities.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive as it reflects a director's increased stake in the company through stock options, suggesting confidence in its future.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The vesting of the options is contingent upon the director's continued service, aligning their interests with the company's long-term success.

Industry Context

This is a standard practice for incentivizing company directors and aligning their interests with shareholders.

Stakeholder Impact

• The acquisition of stock options by a director can positively influence shareholder sentiment.

Key Dates